Mr. Teitelbaum has nearly 20 years of healthcare experience, encompassing investment banking, operating and consulting roles. Mr. Teitelbaum has executed numerous M&A and capital raise transactions for a broad array of public and private middle market and emerging growth companies in the life sciences, healthcare information technology and healthcare services sectors. Prior to joining Burnham Securities in 2007, Mr. Teitelbaum was a senior healthcare banker with Glocap Advisors. Mr. Teitelbaum also previously served as the head of the healthcare group at Cascadia Capital and was a member of the healthcare investment banking groups at Nexus Health Capital, Robertson Stephens and Salomon Brothers Inc. Prior to investment banking, Mr. Teitelbaum worked in pharmaceutical business development, sales and disease management roles at American Cyanamid (now Wyeth, Inc.) and Schering-Plough. Mr. Teitelbaum has served as a healthcare consultant to the FDA and EPA, and conducted genetic research at the Weizmann Institute of Science in Israel. Mr. Teitelbaum received a BA in Biology from the University of Pennsylvania and a MBA from the Wharton School of the University of Pennsylvania.